V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 250007583 | 250005295 | 1.62 | null | Palliative (P) | 2017-12-16 | 2017-12-16 | RUXOLITINIB | Y | N | 250032431 | RITUXIMAB |
| 250007584 | 250005296 | 1.62 | null | Palliative (P) | 2016-08-18 | 2016-08-18 | Capecitabine | N | N | 250032432 | PEG INTERFERON |
| 250007585 | 250005296 | 0 | 0 | Disease modification (D) | 2015-04-16 | 2015-04-16 | Imatinib 400mg | 2 | N | 250032432 | RUXOLITINIB |
| 250007586 | 250005296 | 1.53 | 61 | Disease modification (D) | 2017-10-29 | 2017-10-29 | Cytarabine High Dose | 2 | N | 250032432 | RUXOLITINIB |
| 250007587 | 250005296 | null | 91.5 | Palliative (P) | 2017-10-24 | 2017-11-02 | Rituximab | N | N | 250032432 | DA |
| 250007588 | 250005297 | 1.62 | 70.7 | Curative (C) | 2017-11-06 | 2017-11-06 | RUXOLITINIB | N | N | 250032449 | PEG INTERFERON |
| 250007589 | 250009775 | 1.7 | null | null | 2017-10-05 | 2017-10-05 | RUXOLITINIB | Y | null | 250032451 | RUXOLITINIB |
| 250007590 | 250005298 | null | 58.95 | Not known (9) | 2013-04-21 | 2013-05-05 | RUXOLITINIB | N | null | 250032453 | RUXOLITINIB |
| 250007591 | 250005299 | 1.78 | 67.7 | Disease modification (D) | 2013-06-02 | 2013-06-03 | RUXOLITINIB | N | N | 250032454 | RUXOLITINIB |
| 250007592 | 250005300 | 1.67 | null | Curative (C) | 2015-01-04 | 2015-01-04 | BUSULFAN | N | N | 250032455 | RUXOLITINIB |
| 250007593 | 250005301 | null | 86.6 | Not known (9) | 2013-09-03 | 2013-09-03 | Bortezomib + Cyclophos + Dex | 02 | null | 250032456 | PEG INTERFERON |
| 250007594 | 250005302 | 1.81 | 73.4 | Curative (C) | 2015-11-22 | 2015-11-22 | RUXOLITINIB | 2 | N | 250032457 | AZACITIDINE |
| 250007595 | 250005302 | null | 73 | Disease modification (D) | null | 2018-06-25 | RUXOLITINIB | Y | N | 250032457 | RITUXIMAB |
| 250007596 | 250005303 | 1.92 | null | Disease modification (D) | 2015-08-06 | 2015-08-06 | RUXOLITINIB | N | N | 250032459 | RUXOLITINIB |
| 250007597 | 250005303 | 1.7 | 76.3 | null | 2016-02-17 | 2016-08-10 | Busulfan Oral | null | null | 250032459 | PEG INTERFERON |
| 250007599 | 250005305 | 1.85 | 64.2 | Curative (C) | 2014-07-28 | 2014-07-28 | RUXOLITINIB | 2 | null | 250032466 | IMATINIB |
| 250007600 | 250005305 | 1.61 | null | Palliative (P) | 2014-11-04 | 2014-11-04 | RUXOLITINIB | 02 | N | 250032466 | RUXOLITINIB |
| 250007601 | 250005305 | null | null | Palliative (P) | 2015-11-16 | 2015-11-16 | Rituximab | N | null | 250032466 | BENDAMUSTINE + RITUXIMAB |
| 250007602 | 250005306 | 1.75 | 65 | Disease modification (D) | 2017-05-22 | 2018-01-30 | RUXOLITINIB | 2 | Y | 250032473 | RUXOLITINIB |
| 250007603 | 250005306 | 1.75 | 59.1 | Curative (C) | 2014-03-03 | 2014-03-24 | IGEV R | Y | N | 250032473 | RUXOLITINIB |
| 250007604 | 250011633 | 0 | 0 | Disease modification (D) | null | 2017-04-15 | RUXOLITINIB | N | N | 250032483 | RUXOLITINIB |
| 250007605 | 250005307 | 1.63 | 88.6 | Disease modification (D) | 2017-04-05 | 2017-07-09 | DA | 02 | N | 250032486 | RUXOLITINIB |
| 250007606 | 250009780 | null | null | Palliative (P) | 2015-03-04 | 2015-03-04 | CARBOPLATIN | N | N | 250032491 | DOCETAXEL + PERTUZUMAB + TRASTUZUMAB |
| 250007607 | 250011634 | 0 | 0 | Disease modification (D) | 2017-08-22 | 2017-08-29 | Trial Unspecified | N | N | 250032493 | CHOP R |
| 250007608 | 250005308 | 1.5 | 71 | Adjuvant (A) | 2017-02-12 | 2017-02-13 | Cisplatin + Vinorelbine (PO) | N | N | 250032495 | CHOP R |
| 250007610 | 250005310 | 1.65 | 0 | Palliative (P) | null | 2014-10-03 | IPILIMUMAB + NIVOLUMAB | N | N | 250032500 | CVP R |
| 250007611 | 250009781 | 1.62 | null | Palliative (P) | 2014-03-22 | 2014-03-23 | Carboplatin + Etoposide iv&po | N | N | 250032501 | TRIAL |
| 250007614 | 250005312 | 1.86 | 67.2 | Curative (C) | 2015-02-27 | 2015-03-11 | CISPLATIN + FLUOROURACIL | 02 | N | 250032506 | CHLORAMBUCIL + RITUXIMAB |
| 250007615 | 250005313 | 0 | 95.7 | Disease modification (D) | 2013-08-17 | 2013-08-24 | PEMBROLIZUMAB | 01 | N | 250032510 | TRIAL |
| 250007616 | 250005313 | null | 82 | Curative (C) | null | 2017-01-23 | Pemetrexed | N | N | 250032510 | TRIAL |
| 250007617 | 250005314 | 1.7 | 0 | Disease modification (D) | 2014-06-12 | 2014-07-03 | CVP R | 02 | N | 250032513 | CISPLATIN + PACLITAXEL |
| 250007618 | 250005315 | null | 86.4 | null | 2016-09-07 | 2016-09-07 | AC | N | N | 250032516 | CARBOPLATIN + VINORELBINE |
| 250007619 | 250009784 | 1.44 | 0 | Palliative (P) | 2017-05-12 | 2017-05-25 | Vinorelbine (oral) | N | N | 250032517 | CARBOPLATIN |
| 250007620 | 250005316 | null | null | Neo-adjuvant (N) | 2017-03-17 | 2017-03-24 | CHOP R - 21 days | N | N | 250032522 | TRIAL |
| 250007621 | 250005316 | null | 84.7 | Palliative (P) | 2013-07-15 | 2013-07-19 | Pemetrexed | N | N | 250032522 | PEMBROLIZUMAB |
| 250007622 | 250005317 | 1.8 | 70 | Palliative (P) | 2017-11-01 | 2017-11-09 | Chlorambucil | 02 | null | 250032531 | TRIAL |
| 250007623 | 250005317 | null | 82 | Palliative (P) | 2018-02-17 | 2018-02-21 | IPM | 01 | N | 250032531 | TRIAL |
| 250007624 | 250005318 | 0 | 80.4 | Disease modification (D) | 2014-01-11 | 2014-01-11 | Trial Unspecified | 2 | N | 250032534 | PEMETREXED |
| 250007625 | 250009787 | 1.68 | 105.5 | null | 2013-12-02 | 2013-12-02 | Trial Unspecified | 02 | N | 250032536 | CYTARABINE |
| 250007626 | 250005319 | 1.68 | 73.8 | Disease modification (D) | 2013-06-26 | 2013-06-26 | Pemetrexed | 2 | N | 250032537 | TRIAL |
| 250007627 | 250005319 | 1.65 | 71.3 | Palliative (P) | 2013-11-18 | 2013-11-18 | Carboplatin AUC 6 - 10 | N | null | 250032537 | CARBOPLATIN |
| 250007628 | 250005319 | 0 | 73.8 | Curative (C) | 2014-06-13 | 2014-06-13 | Liposomal Doxorubicin (Caelyx) | N | N | 250032537 | EOX |
| 250007629 | 250005320 | 1.7 | 67.2 | Disease modification (D) | 2017-03-29 | 2017-03-29 | CVP R | N | N | 250032543 | FEC |
| 250007630 | 250005321 | null | 66.4 | Not known (9) | 2018-03-12 | 2018-03-12 | Trial Unspecified | Y | null | 250032544 | TRIAL |
| 250007631 | 250005322 | null | 68.95 | null | 2014-06-29 | 2014-06-30 | Rituximab | 02 | N | 250032546 | ALEMTUZUMAB + FLUDARABINE + MELPHALAN |
| 250007632 | 250005322 | 1.65 | 82.2 | Palliative (P) | 2013-07-04 | 2013-07-12 | Vinorelbine (oral) | N | N | 250032546 | RUXOLITINIB |
| 250007633 | 250005323 | 1.75 | 100 | Palliative (P) | null | 2013-11-17 | VINORELBINE | N | N | 250032551 | CISPLATIN + VINORELBINE |
| 250007634 | 250005324 | 1.63 | 0 | Palliative (P) | 2014-12-26 | 2015-01-05 | Vinorelbine (oral) | 02 | N | 250032552 | DABRAFENIB |
| 250007635 | 250005324 | 1.72 | 0 | Palliative (P) | 2016-07-04 | 2016-07-18 | Imatinib 400mg | 1 | N | 250032552 | PACLITAXEL + TRASTUZUMAB |
| 250007636 | 250011636 | 1.69 | null | Palliative (P) | 2013-11-10 | 2013-11-12 | VINORELBINE | 02 | N | 250032556 | GEMCARBO |